Page last updated: 2024-12-11

abt-770

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ABT-770: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9869811
CHEMBL ID40143
SCHEMBL ID7503283
MeSH IDM0409609

Synonyms (17)

Synonym
CHEMBL40143 ,
abt-770
bdbm50100927
n-[(s)-2-(4,4-dimethyl-2,5-dioxo-imidazolidin-1-yl)-1-(4''-trifluoromethoxy-biphenyl-4-yloxymethyl)-ethyl]-n-hydroxy-formamide
(s)-n-(1-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-(4''-(trifluoromethoxy)biphenyl-4-yloxy)propan-2-yl)-n-hydroxyformamide
unii-i8nwp25thf
220614-50-6
abt 770
i8nwp25thf ,
n-((1s)-2-(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)-1-(((4'-(trifluoromethoxy)(1,1'-biphenyl)-4-yl)oxy)methyl)ethyl)-n-hydroxyformamide
formamide, n-((1s)-1-((4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)methyl)-2-((4'-(trifluoromethoxy)(1,1'-biphenyl)-4-yl)oxy)ethyl)-n-hydroxy-
SCHEMBL7503283
iihfbhzwjngwrc-inizcteosa-n
n-[(2s)-1-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-[4-[4-(trifluoromethoxy)phenyl]phenoxy]propan-2-yl]-n-hydroxyformamide
Q27280579
(s)-n-(1-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-3-((4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)oxy)propan-2-yl)-n-hydroxyformamide
AKOS040750038

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The (S)-enantiomer, 11 (ABT-770), is orally bioavailable and efficacious in an in vivo model of tumor growth."( Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
Albert, DH; Bauch, JL; Bouska, JJ; Curtin, ML; Davidsen, SK; Dellaria, JF; Elmore, IB; Florjancic, AS; Garland, RB; Gong, J; Goodfellow, CL; Guo, Y; Heyman, HR; Holms, JH; Magoc, TJ; Marcotte, PA; Marsh, KC; Michaelides, MR; Morgan, DW; Steinman, DH; Tapang, P; Wada, CK, 2001
)
0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)4.60000.00020.850210.0000AID108890; AID1863874; AID349373
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)0.00400.00001.284810.0000AID107170; AID1863875; AID349374
Stromelysin-1Homo sapiens (human)IC50 (µMol)0.04200.00001.148410.0000AID107511; AID1863876; AID349375
MatrilysinHomo sapiens (human)IC50 (µMol)10.00000.00142.085910.0000AID107827; AID1863877; AID349378
Matrix metalloproteinase-9Homo sapiens (human)IC50 (µMol)0.12000.00000.705310.0000AID108146; AID1863879; AID349379
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (77)

Processvia Protein(s)Taxonomy
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
proteolysisStromelysin-1Homo sapiens (human)
extracellular matrix disassemblyStromelysin-1Homo sapiens (human)
protein catabolic processStromelysin-1Homo sapiens (human)
regulation of cell migrationStromelysin-1Homo sapiens (human)
collagen catabolic processStromelysin-1Homo sapiens (human)
positive regulation of protein-containing complex assemblyStromelysin-1Homo sapiens (human)
cellular response to reactive oxygen speciesStromelysin-1Homo sapiens (human)
innate immune responseStromelysin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionStromelysin-1Homo sapiens (human)
cellular response to lipopolysaccharideStromelysin-1Homo sapiens (human)
cellular response to amino acid stimulusStromelysin-1Homo sapiens (human)
cellular response to UV-AStromelysin-1Homo sapiens (human)
cellular response to nitric oxideStromelysin-1Homo sapiens (human)
regulation of neuroinflammatory responseStromelysin-1Homo sapiens (human)
response to amyloid-betaStromelysin-1Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processStromelysin-1Homo sapiens (human)
extracellular matrix organizationStromelysin-1Homo sapiens (human)
membrane protein ectodomain proteolysisMatrilysinHomo sapiens (human)
membrane protein intracellular domain proteolysisMatrilysinHomo sapiens (human)
antibacterial peptide secretionMatrilysinHomo sapiens (human)
antibacterial peptide biosynthetic processMatrilysinHomo sapiens (human)
proteolysisMatrilysinHomo sapiens (human)
response to xenobiotic stimulusMatrilysinHomo sapiens (human)
extracellular matrix disassemblyMatrilysinHomo sapiens (human)
positive regulation of cell migrationMatrilysinHomo sapiens (human)
collagen catabolic processMatrilysinHomo sapiens (human)
regulation of cell population proliferationMatrilysinHomo sapiens (human)
defense response to Gram-negative bacteriumMatrilysinHomo sapiens (human)
defense response to Gram-positive bacteriumMatrilysinHomo sapiens (human)
extracellular matrix organizationMatrilysinHomo sapiens (human)
skeletal system developmentMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of protein phosphorylationMatrix metalloproteinase-9Homo sapiens (human)
proteolysisMatrix metalloproteinase-9Homo sapiens (human)
apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
embryo implantationMatrix metalloproteinase-9Homo sapiens (human)
cell migrationMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-9Homo sapiens (human)
macrophage differentiationMatrix metalloproteinase-9Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-9Homo sapiens (human)
cellular response to reactive oxygen speciesMatrix metalloproteinase-9Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of DNA bindingMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
ephrin receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of keratinocyte migrationMatrix metalloproteinase-9Homo sapiens (human)
cellular response to lipopolysaccharideMatrix metalloproteinase-9Homo sapiens (human)
cellular response to cadmium ionMatrix metalloproteinase-9Homo sapiens (human)
cellular response to UV-AMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaMatrix metalloproteinase-9Homo sapiens (human)
regulation of neuroinflammatory responseMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of receptor bindingMatrix metalloproteinase-9Homo sapiens (human)
response to amyloid-betaMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney developmentMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cation channel activityMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activityStromelysin-1Homo sapiens (human)
metalloendopeptidase activityStromelysin-1Homo sapiens (human)
serine-type endopeptidase activityStromelysin-1Homo sapiens (human)
protein bindingStromelysin-1Homo sapiens (human)
peptidase activityStromelysin-1Homo sapiens (human)
metallopeptidase activityStromelysin-1Homo sapiens (human)
zinc ion bindingStromelysin-1Homo sapiens (human)
endopeptidase activityMatrilysinHomo sapiens (human)
metalloendopeptidase activityMatrilysinHomo sapiens (human)
serine-type endopeptidase activityMatrilysinHomo sapiens (human)
protein bindingMatrilysinHomo sapiens (human)
metallopeptidase activityMatrilysinHomo sapiens (human)
zinc ion bindingMatrilysinHomo sapiens (human)
endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
protein bindingMatrix metalloproteinase-9Homo sapiens (human)
collagen bindingMatrix metalloproteinase-9Homo sapiens (human)
peptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metallopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-9Homo sapiens (human)
identical protein bindingMatrix metalloproteinase-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
extracellular regionStromelysin-1Homo sapiens (human)
nucleusStromelysin-1Homo sapiens (human)
mitochondrionStromelysin-1Homo sapiens (human)
cytosolStromelysin-1Homo sapiens (human)
extracellular matrixStromelysin-1Homo sapiens (human)
extracellular spaceStromelysin-1Homo sapiens (human)
extracellular regionMatrilysinHomo sapiens (human)
extracellular matrixMatrilysinHomo sapiens (human)
extracellular exosomeMatrilysinHomo sapiens (human)
extracellular spaceMatrilysinHomo sapiens (human)
extracellular regionMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
collagen-containing extracellular matrixMatrix metalloproteinase-9Homo sapiens (human)
extracellular exosomeMatrix metalloproteinase-9Homo sapiens (human)
tertiary granule lumenMatrix metalloproteinase-9Homo sapiens (human)
ficolin-1-rich granule lumenMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID107511Inhibition of Matrix metalloprotease-32001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID108146Inhibition of matrix metalloprotease-92001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID7743Half-life was determined in monkey after 3 mg/kg of i.v. dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID1863879Inhibition of MMP-9 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1863923Half life in cynomolgus monkey at 3 mg/kg, iv2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID38065Maximal effective dose against growth of B16 melanoma cells implanted subcutaneously in flank of mice2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID1863922Half life in dog at 3 mg/kg, iv2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID349375Inhibition of MMP32008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
AID1863930Metabolic stability in rat assessed as clearance at 3 mg/kg, iv2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1863875Inhibition of MMP-2 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID9883Volume of distribution was determined in dog after a 3 mg/kg of iv dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID11380Plasma clearance value was determined in rat after a 3 mg/kg of iv dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID1863931Metabolic stability in dog assessed as clearance at 3 mg/kg, iv2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID349378Inhibition of MMP72008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
AID349379Inhibition of MMP92008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
AID1863928Plasma concentration in dog at 3 mg/kg, iv measured upto 3 hrs2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1863926Oral bioavailability in cynomolgus monkey at 3 mg/kg2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID7341Absolute bioavailability was evaluated in monkey2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID108890In vitro inhibition of human Matrix metalloprotease-1.2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID349374Inhibition of MMP22008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
AID1863876Inhibition of MMP-3 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1863929Plasma concentration in cynomolgus monkey at 3 mg/kg, iv measured upto 3 hrs2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID12811Absolute bioavailability was evaluated in rat2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID1863877Inhibition of MMP-7 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID131832Increase in life span corresponding to 6.5 day delay to 1 g tumor weight at 100 mg/kg of oral dose in mice2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID10912Volume of distribution was determined in rat after a 3 mg/kg of iv dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID8310Area under curve was determined in dog after a 3 mg/kg of oral dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID1863921Half life in rat at 3 mg/kg, iv2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1863933Antitumor activity in mouse B16-F10 xenografted C57BL mouse lung metastasis model assessed as increase in life span measured per hour at 100 mg/kg, ip bid2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID8747Plasma clearance value was determined in dog after a 3 mg/kg of iv dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID10098Half-life was determined in dog after a3 mg/kg of iv dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID1863932Metabolic stability in cynomolgus monkey assessed as clearance at 3 mg/kg, iv2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID1863924Oral bioavailability in rat at 3 mg/kg2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID7317Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID1863927Plasma concentration in rat at 3 mg/kg, iv measured upto 3 hrs2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID107827Inhibition of Matrix metalloprotease-72001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID12183Area under curve was determined in rat after a 3 mg/kg of oral dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID107170In vitro inhibition of human Matrix metalloprotease-2.2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID9115Absolute bioavailability was evaluated in dog2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID1863874Inhibition of MMP-1 (unknown origin)2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID7562Volume of distribution was determined in monkey after a 3 mg/kg of iv dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
AID1863925Oral bioavailability in dog at 3 mg/kg2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID349373Inhibition of MMP12008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
AID10226Area under curve was determined in monkey after a 3 mg/kg of oral dose2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's1 (16.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.41 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]